Ohio State Navbar

EXPERIMENTAL AGENT MAY HELP OLDER PEOPLE WITH CHRONIC LEUKEMIA


The experimental drug ibrutinib (PCI-32765) shows great promise for treating elderly patients with chronic lymphocytic leukemia (CLL), according to interim findings from a phase I/II clinical trial co-led by researchers at the OSUCCC – James and M.D. Anderson Cancer Center. The study indicates that the oral agent has few side effects and a high one-year survival rate in older patients. Read more: